Early symptom aggravation following ulnar nerve transposition for cubital tunnel syndrome: incidence, predictive factors, and threshold-based risk stratification

尺神经移位术治疗肘管综合征后早期症状加重:发生率、预测因素和基于阈值的风险分层

阅读:1

Abstract

Early postoperative symptom aggravation is a clinically relevant yet underexplored phenomenon following anterior ulnar nerve transposition for cubital tunnel syndrome (CuTS). This study aimed to define its incidence, identify predictive factors, and establish a threshold-based risk stratification model. We retrospectively reviewed 127 patients undergoing anterior subcutaneous transposition of the ulnar nerve between 2020 and 2023. Early symptom aggravation was defined as a postoperative deterioration in at least one clinical (VAS or PRUNE) or electrophysiological (CMAP or SNCV) indicator at two weeks post-surgery. Multivariate logistic regression and ROC curve analyses were performed to determine independent predictors and optimal thresholds. Early symptom aggravation occurred in 26.8% of patients. Multivariate analysis identified symptom duration (OR = 1.150, p < 0.001) as a significant independent predictor. McGowan grade III showed a moderate association (OR = 3.224, p = 0.087). ROC analysis revealed excellent discriminative ability for symptom duration (AUC = 0.890) with an optimal threshold of 24.00 months (sensitivity 82.4%, specificity 86.2%). Other variables, including electrophysiological measures and demographics, demonstrated limited predictive value. Symptom duration and preoperative McGowan grade are key risk factors for early symptom aggravation after CuTS surgery. A simple threshold-based model can aid in preoperative counseling and expectation management. These findings highlight the need for timely surgical intervention to minimize neural deterioration and improve short-term outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10143-025-03992-2.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。